A federal appeals court has set the timeline for a renewed legal challenge to the Trump administration's Medicare hemp coverage program, which provides up to $500 annually in hemp-derived products for qualifying beneficiaries.
The case, originally dismissed by Judge Trevor N. McFadden in May, brings together an unusual coalition of anti-marijuana advocacy organizations and a cannabis-focused biopharmaceutical company. They're arguing the coverage program exceeds federal authority under current law.
The appeals court's scheduling order breathes new life into a lawsuit that could determine whether Medicare can reimburse seniors for CBD oils, topicals, and other hemp products marketed for pain, anxiety, and sleep issues.
The Legal Arguments
The challengers claim the administration lacked authority to implement the hemp coverage benefit without explicit congressional approval. Hemp products, while federally legal under the 2018 Farm Bill, occupy a regulatory gray zone when it comes to health insurance coverage.
Medicare traditionally covers FDA-approved drugs and certain medical devices. Hemp-derived CBD products, despite widespread consumer use, have limited FDA approval. Only one prescription CBD medication, Epidiolex for epilepsy, has full agency authorization.
The biopharmaceutical company's involvement adds a commercial dimension. Companies developing cannabis-based prescription drugs have argued that over-the-counter hemp products create unfair competition and muddy the regulatory waters.
Industry Impact
The $500 annual benefit has become a significant revenue driver for hemp retailers and manufacturers since its implementation. Industry analysts estimate the program could funnel hundreds of millions of dollars annually into the hemp sector if it survives legal scrutiny.
But the lawsuit has created uncertainty. Some retailers have hesitated to invest in Medicare-focused marketing while the program's future remains in question. Others have rushed to capture market share before a potential court reversal.
The case also highlights tensions within the cannabis industry itself. Traditional pharmaceutical companies pursuing FDA approval face years of clinical trials and regulatory review. Meanwhile, hemp companies sell similar compounds with minimal oversight, often making health claims that would trigger FDA enforcement in other contexts.
What's Next
The appeals court will hear oral arguments later this year, with a decision likely in early 2025. If the program survives, it could set a precedent for broader cannabis coverage under federal health programs.
The Centers for Medicare & Medicaid Services has defended the program, arguing that the 2018 Farm Bill's legalization of hemp provides sufficient authority. The agency points to hemp's safety profile and widespread state-level acceptance as medical treatment.
Anti-marijuana groups counter that safety and legality don't automatically translate to insurance coverage authority. They've cited concerns about product quality, inconsistent dosing, and lack of clinical evidence for many hemp product claims.
The outcome could shape how other federal agencies approach cannabis-related benefits. The Department of Veterans Affairs, for instance, has faced similar questions about covering cannabis treatments for veterans despite federal prohibition of marijuana.
This article is based on original reporting by www.marijuanamoment.net.
